S100A4 and cardiomyopathy: Based on our comprehensive single-cell characterization of SMC subsets in cardiomyopathy, as well as analysis of relevant transcriptional regulatory networks and in vitro experimental validation, our study concludes that C6 S100A4+ SMCs exhibit increased sensitivity to adverse events associated with cardiomyopathy.